Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Opthea Limited - news published 138 - readings 1.196

BACK

Opthea Limited

Opthea Announces Decision to Discontinue Wet AMD Trials (Form 6-K)

Opthea Announces Decision to Discontinue Wet AMD Trials ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Comp ...

31.03.2025

Opthea Limited

Opthea Announces COAST Phase 3 Trial Topline Results (Form 6-K)

Opthea Announces COAST Phase 3 Trial Topline Results COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern Melbourne, Australia, and Princeton, N.J., 24 March, 2025 -- Opthea Limited (ASX/NASDAQ: OPT, &q ...

24.03.2025

Opthea Limited

Opthea Announces COAST Phase 3 Trial Topline Results

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company&q ...

24.03.2025

Opthea Limited

Opthea Announces Phase 2b Wet AMD Publication

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Opthea Limited published this content on March 03, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 03, 2025 at 12:12:18.460 .

03.03.2025

Opthea Limited

Opthea Announces Phase 2b Wet AMD Publication (Form 6-K)

Opthea Announces Phase 2b Wet AMD Publication Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina Melbourne, Australia and Princeton, NJ, March 3, 2025 -- Opthea Limited (ASX/NASDAQ: OPT "Opthea", the "Company"), a clinical-stage biopharmaceutical compa ...

03.03.2025

Opthea Limited

Opthea Reports Half Year Results and Business Updates

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Opthea Limited published this content on February 28, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 28, 2025 at 12:31:11.411 .

28.02.2025

Opthea Limited

Opthea Reports Half Year Results and Business Updates (Form 6-K)

Opthea Reports Half Year Results and Business Updates Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (mid-CY25) Melbourne, Australia, and Princeton, NJ, US, February 28, 2025 -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical- ...

28.02.2025

Opthea Limited

Opthea Completes Drug Product PPQ Campaign (Form 6-K)

Opthea Completes Drug Product PPQ Campaign Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 Melbourne, Australia, and Princeton, NJ, US, February 26, 2025 -- Opthea Limited (ASX/NASDAQ: OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing no ...

26.02.2025

Opthea Limited

Opthea Completes COAST Final Week 52 Patient Visit (Form 6-K)

Opthea Completes COAST Final Week 52 Patient Visit COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMD Company confirms topline results for COAST anticipated in early 2Q CY25 Melbourne, Australia, and Princeton, NJ, US, February 18, 2025 -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a cli ...

18.02.2025

Opthea Limited

Opthea to Present at Oppenheimer Healthcare Conference

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Opthea Limited published this content on February 07, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 07, 2025 at 12:45:22.038 .

07.02.2025

Opthea Limited

Opthea to Present at Oppenheimer Healthcare Conference (Form 6-K)

Opthea to Present at Oppenheimer Healthcare Conference Melbourne, Australia, and Princeton, NJ, US, February 7, 2025 -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet ...

07.02.2025

Opthea Limited

Opthea Wet AMD Data Featured at Macula Society Meeting (Form 6-K)

Opthea Wet AMD Data Featured at Macula Society Meeting Melbourne, Australia, and Princeton, NJ, US, February 6, 2025 -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet ...

06.02.2025

Opthea Limited

Press Release - Opthea Investor Day (Form 6-K)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Opthea Limited published this content on January 28, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on January 28, 2025 at 18:33:19.140 .

28.01.2025

Opthea Limited

Opthea Corporate Presentation - January 2025

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Opthea Limited published this content on January 13, 2025 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 13, 2025 at 21:17:14.994 .

13.01.2025

Opthea Limited

Opthea Corporate Presentation Jan 2025 Form 6 K

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Opthea Limited published this content on January 13, 2025 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 13, 2025 at 12:26:36.985 .

13.01.2025

Opthea Limited - news published 138 - readings 1.196

Opthea Limited

Opthea Announces Decision to Discontinue Wet AMD Trials (Form 6-K)

Opthea Limited

Opthea Announces COAST Phase 3 Trial Topline Results (Form 6-K)

Opthea Limited

Opthea Announces COAST Phase 3 Trial Topline Results

Opthea Limited

Opthea Announces Phase 2b Wet AMD Publication

Opthea Limited

Opthea Announces Phase 2b Wet AMD Publication (Form 6-K)

Opthea Limited

Opthea Reports Half Year Results and Business Updates

Opthea Limited

Opthea Reports Half Year Results and Business Updates (Form 6-K)

Opthea Limited

Opthea Completes Drug Product PPQ Campaign (Form 6-K)

Opthea Limited

Opthea Completes COAST Final Week 52 Patient Visit (Form 6-K)

Opthea Limited

Opthea to Present at Oppenheimer Healthcare Conference

Opthea Limited

Opthea to Present at Oppenheimer Healthcare Conference (Form 6-K)

Opthea Limited

Opthea Wet AMD Data Featured at Macula Society Meeting (Form 6-K)

Opthea Limited

Press Release - Opthea Investor Day (Form 6-K)

Opthea Limited

Opthea Corporate Presentation - January 2025

Opthea Limited

Opthea Corporate Presentation Jan 2025 Form 6 K

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member